Singapore workshop turns WHO trial guidance into hands-on training
The WHO and the Advancing Clinical Evidence in Infectious Diseases Network used a Singapore workshop to move clinical trial guidance out of the page and into practice. Held from 31 August to 2 September 2026, the ADVANCE-ID Clinical Trial Workshop 2026 brought together researchers, clinicians, clinician-scientists and trial specialists for focused training on the design and conduct of high-quality studies.
The format was deliberately practical. Rather than stopping at lecture-style instruction, the program asked participants to work through the full trial pathway, from framing a credible research question to selecting an appropriate study design, applying statistical methods, testing feasibility, planning implementation and preparing for dissemination. In clinical research, those steps are inseparable. A weak question wastes resources, a mismatched design distorts the answer, and a trial that cannot be implemented in the real world may never change care.
The workshop aligned directly with WHO guidance on best practices for clinical trials and with the WHO Good Practices for Clinical Trial Design and Implementation online course, which participants completed before arriving in Singapore. That sequencing created a bridge between self-paced learning and live problem-solving. It also reflected a broader problem in global research: many investigators have exposure to trial concepts, but fewer have structured opportunities to convert that knowledge into protocol development, statistical reasoning and operational planning.
One sentence captures the urgency of the exercise: trial quality is built long before the first patient is enrolled.
Mentored proposal development and peer review shaped the agenda
Seventy-seven participants took part in the two-and-a-half-day program, with an international faculty of clinical trial specialists supporting mentored group work. Participants were not passive listeners. They developed and refined research ideas with input from clinical trial specialists, statisticians and public engagement experts, then presented their proposals in brief pitch sessions before receiving expert feedback.
This type of workshop matters because trial design errors usually begin early, often in ways that are not obvious until the study is already expensive, slow or underpowered. A clear endpoint may still be clinically irrelevant if the question does not match the disease burden. Statistical plans can look elegant on paper while failing to account for recruitment constraints, missing data, site heterogeneity or limited diagnostic access. Working through those problems in real time gives investigators a better chance of building studies that can survive operational pressure.
The discussions also addressed obstacles that repeatedly slow clinical trials in low- and middle-income countries. Research infrastructure remains uneven, regulatory and ethical processes can be cumbersome, diagnostic capacity may be limited, and site readiness is not guaranteed. Equity and inclusion were also part of the conversation, along with public engagement. These are not peripheral issues. They shape who gets enrolled, which populations are represented and whether findings can be generalized beyond a narrow setting.
Cross-regional participation broadened the research exchange
A substantial feature of the workshop was its cross-regional composition. With WHO support, 10 participants nominated by the WHO Regional Office for Africa joined the meeting. They came from institutions in Cameroon, Gabon, Ghana, Kenya, Senegal, Uganda and Zambia and included clinical investigators, project implementers, lecturers and trial platform managers. Their presence brought direct experience from diverse research environments and created a setting for exchange across different health systems and trial infrastructures.
A clinician-researcher from Kazakhstan also attended, selected from alumni of the Summer School on Clinical Research held in June and July 2026 with WHO support. That continuity linked national capacity-building work to a wider international network of trial expertise. The workshop therefore functioned as more than a single training event. It connected regional initiatives, professional relationships and long-term collaboration across countries and disciplines.
The value of that mix is straightforward. Trial ecosystems do not strengthen in isolation. Investigators working in Africa, Asia and Europe face overlapping problems, but they often approach them with different regulatory frameworks, funding realities and site capacities. Putting those perspectives in the same room speeds practical learning and exposes participants to methods that can be adapted rather than copied.
WHO and ADVANCE-ID extend the training beyond the workshop dates
Learning from the Singapore meeting is designed to continue after the in-person sessions ended. WHO and ADVANCE-ID are supporting Advancing Clinical Trials: a statistical guide, a free modular seminar series intended to help non-statisticians understand the statistical concepts that underpin trial design and analysis. For many investigators, this kind of support is essential. Statistical literacy is not a narrow technical luxury; it is the difference between a protocol that can answer its question and one that collapses under scrutiny.
ADVANCE-ID has also been designated as a WHO collaborating centre for clinical trials, giving the network an additional formal pathway for ongoing cooperation with WHO. The workshop and the related training activities support implementation of World Health Assembly resolution WHA75.8 on strengthening clinical trials, WHO guidance for best practices, and the Global action plan for clinical trial ecosystem strengthening.
The public health implications are concrete. Stronger trial capacity means better evidence generation, more credible local research leadership and a greater ability to test interventions in settings where infectious diseases continue to impose a major burden. It also means that the people designing studies are more likely to understand the practical barriers that shape enrollment, follow-up, retention and dissemination.
A workshop cannot solve every structural weakness in global trial infrastructure. It can, however, sharpen the skills of investigators who will shape the next wave of studies, and it can build relationships that outlast a single meeting in Singapore. The remaining challenge lies in sustaining that momentum, translating training into functioning protocols, and ensuring that capacity growth reaches the sites and systems where evidence generation is still most constrained.